scholarly journals The lingering mysteries of metastatic recurrence in breast cancer

2020 ◽  
Vol 124 (1) ◽  
pp. 13-26
Author(s):  
Alessandra I. Riggio ◽  
Katherine E. Varley ◽  
Alana L. Welm
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Disease ◽  
Systemic Therapy ◽  
Initial Diagnosis ◽  
Diagnosis And Treatment ◽  
Breast Cancer Patients ◽  
Key Factors ◽  
Metastatic Recurrence ◽  
Metastatic Relapse

AbstractDespite being the hallmark of cancer that is responsible for the highest number of deaths, very little is known about the biology of metastasis. Metastatic disease typically manifests after a protracted period of undetectable disease following surgery or systemic therapy, owing to relapse or recurrence. In the case of breast cancer, metastatic relapse can occur months to decades after initial diagnosis and treatment. In this review, we provide an overview of the known key factors that influence metastatic recurrence, with the goal of highlighting the critical unanswered questions that still need to be addressed to make a difference in the mortality of breast cancer patients.

Outcome of HER2-positive breast cancer patients following metastatic relapse after adjuvant trastuzumab treatment since EMA regulatory approval.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 641-641 ◽  
Author(s):  
Jean-Philippe Spano ◽  
Stéphane Vignot ◽  
Xuan Dung Ho ◽  
Nayi Zongo ◽  
Celine Magneux ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Disease ◽  
Breast Cancer Patients ◽  
Time To Progression ◽  
Her2 Positive ◽  
Adjuvant Trastuzumab ◽  
Her2 Positive Breast Cancer ◽  
Metastatic Relapse ◽  
Positive Breast Cancer

641 Background: Trastuzumab, a humanized monoclonal antibody against human epidermal growth factor receptor 2 (HER2) is approved in France since 2005 for HER2-positive breast cancer patients in the adjuvant setting. Efficacy of this treatment is clearly established but little is known related to patient outcome if they develop metastatic relapse after adjuvant trastuzumab. The aim of this study is to analyse these relapses with a special focus on efficacy of anti-HER2 treatment in this setting. Methods: We analysed 456 patients with HER2-positive early breast cancer treated with trastuzumab containing adjuvant therapy between 2006 and 2011 in two Departments of Medical Oncology from Université Pierre et Marie Curie, Paris, France. Data from patients with metastatic relapse were identified. Disease free survival (DFS) between end of trastuzumab and relapse, quality of response, and time to progression after anti-HER2 new treatment are reported. Results: Relapse rate was 3.3 % after adjuvant trastuzumab (15 pts, median age 53 years, ER+ 40 %). DFS between end of trastuzumab and relapse was 244 days (95% CI: 91 - 397 days). One pt actually had a confirmed HER2-negative metastatic disease. The other 14 pts were treated with anti-HER2 agents at relapse. On 12 evaluable pts, an objective response was observed in 8 pts, stabilisation in 2 pts and progression in 2 pts. Median time to progression after first line metastatic treatment was 222 days (95% CI: 114 - 330 days). Additional data about site of relapse and subsequent therapies are available. Conclusions: Relapse after adjuvant trastuzumab remains a rare event in this real life cohort of breast cancer pts. For these pts, we will present data of the patterns of relapse and response. These data may help us to determine if adjuvant trastuzumab has an impact on outcome of HER2 metastatic disease compared to data in trastuzumab naive metastatic HER2-positive breast cancer pts. We also plan to seek international collaboration to expand our analyses, as well as overall survival.

scholarly journals MRI-Based Radiomics Analysis for the Pretreatment Prediction of Pathologic Complete Tumor Response to Neoadjuvant Systemic Therapy in Breast Cancer Patients: A Multicenter Study

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2447
Author(s):  
Renée W. Y. Granzier ◽  
Abdalla Ibrahim ◽  
Sergey P. Primakov ◽  
Sanaz Samiei ◽  
Thiemo J. A. van Nijnatten ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Systemic Therapy ◽  
Tumor Response ◽  
Added Value ◽  
Breast Cancer Patients ◽  
Neoadjuvant Systemic Therapy ◽  
Clinical Models ◽  
Combined Models ◽  
Complete Tumor

This retrospective study investigated the value of pretreatment contrast-enhanced Magnetic Resonance Imaging (MRI)-based radiomics for the prediction of pathologic complete tumor response to neoadjuvant systemic therapy in breast cancer patients. A total of 292 breast cancer patients, with 320 tumors, who were treated with neo-adjuvant systemic therapy and underwent a pretreatment MRI exam were enrolled. As the data were collected in two different hospitals with five different MRI scanners and varying acquisition protocols, three different strategies to split training and validation datasets were used. Radiomics, clinical, and combined models were developed using random forest classifiers in each strategy. The analysis of radiomics features had no added value in predicting pathologic complete tumor response to neoadjuvant systemic therapy in breast cancer patients compared with the clinical models, nor did the combined models perform significantly better than the clinical models. Further, the radiomics features selected for the models and their performance differed with and within the different strategies. Due to previous and current work, we tentatively attribute the lack of improvement in clinical models following the addition of radiomics to the effects of variations in acquisition and reconstruction parameters. The lack of reproducibility data (i.e., test-retest or similar) meant that this effect could not be analyzed. These results indicate the need for reproducibility studies to preselect reproducible features in order to properly assess the potential of radiomics.

Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients

2011 ◽  
Vol 130 (1) ◽  
pp. 255-266 ◽  
Author(s):  
Suja S. Rajan ◽  
Sally C. Stearns ◽  
Gary H. Lyman ◽  
William R. Carpenter
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Systemic Therapy ◽  
Breast Cancer Patients

Screening for metastatic disease in newly diagnosed breast cancer patients

2008 ◽  
Vol 6 (7) ◽  
pp. 61
Author(s):  
E. Una ◽  
M.J. Borau ◽  
J. Nieto ◽  
A. De la Torre ◽  
G. Fernandez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Disease ◽  
Newly Diagnosed ◽  
Breast Cancer Patients

Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy

2021 ◽  
Author(s):  
Leisha C. Elmore ◽  
Henry M. Kuerer ◽  
Carlos H. Barcenas ◽  
Benjamin D. Smith ◽  
Makesha V. Miggins ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Systemic Therapy ◽  
Clinical Course ◽  
Breast Cancer Patients ◽  
Neoadjuvant Systemic Therapy

Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients

2013 ◽  
Vol 139 (6) ◽  
pp. 1005-1013 ◽  
Author(s):  
Patricia Diana Sørensen ◽  
Erik Hugger Jakobsen ◽  
Jonna Skov Madsen ◽  
Eva Brix Petersen ◽  
Rikke Fredslund Andersen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Predictive Values ◽  
Metastatic Recurrence ◽  
Her 2 ◽  
Sensitivity Specificity

scholarly journals Key Factors Contributing to Quality of Life for Breast Cancer Patients in Latvia: Supplementing Quantitative Surveys with Qualitative Interviews

2012 ◽  
Vol 12 (1) ◽  
pp. 3-10 ◽  
Author(s):  
Agnese Dzērvīte ◽  
Maruta Pranka ◽  
Tana Lace ◽  
Ritma Rungule ◽  
Edvins Miklasevics ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Patients ◽  
Qualitative Interviews ◽  
Treatment Strategies ◽  
Well Being ◽  
University Hospital ◽  
Breast Cancer Patients ◽  
Key Factors

Summary Introduction. Health related quality of life is a much debated topic in medicine with much quantitative and qualitative research contributing to the understanding of how to improve the lives of patients, yet little has been published in relation to the quality of life of Latvian breast cancer patients. Aim of the Study. To gather base measurements of subjective and objective quality of life factors for breast cancer patients in Latvia and discover which key factors contribute most to quality of life of Latvian breast cancer patients at the start of treatment. Materials and Methods. This paper presents data collected from April 2010 to June 2011 at the Pauls Stradins Clinical University hospital on key factors influencing quality of life for breast cancer patients: health and physical well-being; state of surroundings and environment; social support and functionality; financial state, employment and leisure. Quantitative survey material has been supplemented with insight from qualitative in-depth interviews to better explain the objective and subjective implications for breast cancer patients’ quality of life. Results. Interviewed breast cancer patients rated their quality of life as being average or good at the beginning of treatment. Negative factors contributing to lowered quality of life were mainly linked to patient financial, social and emotional state at the first weeks of treatment and correspond to previous research done in Latvia on quality of life issues. Conclusions. Further follow-up surveys will contribute to the evaluation of breast cancer patients’ needs while undergoing treatment to further improve treatment strategies, especially if validated quality of life measurement surveys were to be implemented in Latvian hospitals.

Sign in / Sign up

Export Citation Format

Share Document